A5056190969- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Neutropenia and Cancer Infections
- Atrial Fibrillation Management and Outcomes
- Complement system in diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Cancer Genomics and Diagnostics
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Circadian rhythm and melatonin
- Biochemical Analysis and Sensing Techniques
- Sleep and Wakefulness Research
- T-cell and B-cell Immunology
- Chemokine receptors and signaling
- Plant-based Medicinal Research
- Receptor Mechanisms and Signaling
- Renal Diseases and Glomerulopathies
- Multiple Myeloma Research and Treatments
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Coronary Interventions and Diagnostics
- Diabetes Treatment and Management
- Pharmacogenetics and Drug Metabolism
- Regulation of Appetite and Obesity
Freie Universität Berlin
2016-2023
Idorsia (Switzerland)
2019-2023
Boehringer Ingelheim (United States)
2023
Columbus Oncology and Hematology Associates
2020
University of Potsdam
2017-2020
University of St. Gallen
2017-2020
Roche (Switzerland)
2020
University of Florida
2020
University of Bonn
2017
Abstract Aims Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab ravulizumab. showed efficacy safety comparable the pivotal COMMODORE 2 supporting studies. Methods We characterized crovalimab pharmacokinetics relationship between exposure pharmacokinetic parameters pharmacodynamic biomarkers, endpoints using pooled data (healthy...
Paclitaxel is a commonly used cytotoxic anticancer drug with potentially life-threatening toxicity at therapeutic doses and high interindividual pharmacokinetic variability. Thus, effect monitoring indicated to control dose-limiting neutropenia. Joerger et al. (2016) developed dose individualization algorithm based on (PK)/pharmacodynamic (PD) model describing paclitaxel neutrophil concentrations. Furthermore, the was prospectively compared in clinical trial against standard dosing (Central...
Paclitaxel/platinum chemotherapy, the backbone of standard first-line treatment advanced non-small cell lung cancer (NSCLC), exhibits high interpatient variability in response and toxicity burden. Baseline blood biomarker concentrations tumor size (sum diameters) at week 8 relative to baseline (RS8) are widely investigated prognostic factors. However, joint analysis data on demographic/clinical characteristics, levels, chemotherapy exposure-driven early for improved prediction overall...
The C-X-C chemokine receptor 7 (CXCR7) has evolved as a promising, druggable target mainly in the immunology and oncology fields modulating plasma concentrations of its ligands CXCL11 CXCL12 through receptor-mediated internalization. This "scavenging" activity creates concentration gradients these between blood vessels tissues that drive directional cell migration. randomized, double-blind, placebo-controlled first-in-human study assessed safety, tolerability, pharmacokinetics,...
Selatogrel is a potent and reversible P2Y12 receptor antagonist developed for subcutaneous self-administration by patients with suspected acute myocardial infarction. After single-dose emergency treatment selatogrel, are switched to long-term oral antagonists. shows rapid onset offset of inhibition platelet aggregation (IPA) overcome the critical initial time after Long-term benefit provided antagonists such as clopidogrel, prasugrel, ticagrelor. A population pharmacokinetic...
Paclitaxel-associated peripheral neuropathy (PN), a major dose-limiting toxicity, significantly impacts patients' quality of life/treatment outcome. Evaluation risk factors often ignores time PN onset, precluding the impact time-dependent factors, e.g., drug exposure, needed to comprehensively characterize PN. We employed parametric time-to-event (TTE) analysis describe course first occurrence clinically relevant grades ≥2 (PN2+, <i>n</i> = 105, common terminology criteria v4.0) and...
The P2Y
Abstract The current trend for clinical pharmacology is toward more complex studies (eg, umbrella protocols covering single and multiple ascending doses, food effect, metabolism pathways), requiring many decisions to be made during their conduct. This article discusses guidance of such early by modeling simulation. ability make use all available information each time new data become the study requires scientist unblinded. must course not jeopardize blinding team, this how unblinding can...